Advances in the Management of HPV-Related Oropharyngeal Cancer

Patients with human papillomavirus- (HPV-) related oropharyngeal squamous cell carcinoma (OPSCC) have a better prognosis than HPV-negative OPSCC when treated with standard high-dose cisplatin-based chemoradiotherapy. Consistent with this assertion and due to younger age at diagnosis, novel approache...

Full description

Bibliographic Details
Main Authors: F. De Felice, V. Tombolini, V. Valentini, M. de Vincentiis, S. Mezi, O. Brugnoletti, A. Polimeni
Format: Article
Language:English
Published: Hindawi Limited 2019-01-01
Series:Journal of Oncology
Online Access:http://dx.doi.org/10.1155/2019/9173729
Description
Summary:Patients with human papillomavirus- (HPV-) related oropharyngeal squamous cell carcinoma (OPSCC) have a better prognosis than HPV-negative OPSCC when treated with standard high-dose cisplatin-based chemoradiotherapy. Consistent with this assertion and due to younger age at diagnosis, novel approaches to minimize treatment sequelae while preserving survival outcomes become of paramount importance. Here, we critically reviewed the evidence-based literature supporting the deintensification strategies in HPV-related OPSCC management, including radiotherapy dose and/or volume reduction, replacement of cisplatin radiosensitising chemotherapy, and the use of transoral surgery. Undoubtedly, further researches are needed before changing the standard of care in this setting of patients.
ISSN:1687-8450
1687-8469